Heart Valve Development
Regulatory Networks in Development and Disease
Abstract: In recent years, significant advances have been made in the definition of regulatory pathways that control normal and abnormal cardiac valve development. Here, we review the cellular and molecular mechanisms underlying the early development of valve progenitors and establishment of normal valve structure and function. Regulatory hierarchies consisting of a variety of signaling pathways, transcription factors, and downstream structural genes are conserved during vertebrate valvulogenesis. Complex intersecting regulatory pathways are required for endocardial cushion formation, valve progenitor cell proliferation, valve cell lineage development, and establishment of extracellular matrix compartments in the stratified valve leaflets. There is increasing evidence that the regulatory mechanisms governing normal valve development also contribute to human valve pathology. In addition, congenital valve malformations are predominant among diseased valves replaced late in life. The understanding of valve developmental mechanisms has important implications in the diagnosis and management of congenital and adult valve disease.
This Review is part of a thematic series on Developmental Biology, which includes the following articles:
Signaling Pathways Controlling Second Heart Field Development [2009;104:933–942]
Heart Valve Development: Regulatory Networks in Development and Disease
The Forgotten Lineage: Cardiac Fibroblasts and the Role of Periostin
Conduction System Specification
Coronary Artery Development–Myocardial Vessel Interaction
Elizabeth McNally Editor
Defective development of the heart valves occurs in 20% to 30% of congenital cardiovascular malformations, and the incidence of congenital valve malformations has been estimated as high as 5% of live births.1,2 Heart valve replacement is the second most common cardiac surgery in the United States, and the majority of replaced aortic valves have congenital malformations.3,4 Developmental defects in valve structure and function occur in several syndromes with identified genetic lesions, including trisomy 21, Noonan, Marfan, Williams, and Holt–Oram syndromes.5 Additional isolated gene mutations have been associated with valve development and disease.6–8 However, in many cases, the underlying causes of valve developmental anomalies and associated dysfunction have not been identified. Here, we review studies of heart valve development and related disease mechanisms in animal models and in tissue culture. These research efforts provide extensive information on the molecular mechanisms and cellular events that govern the initial formation, maturation and function of heart valves with implications for development of new therapies for valve disease.
Overview of Valve Development
The 4-chambered vertebrate heart has aortic and pulmonic semilunar (SL) valves at the arterial pole as well as mitral and tricuspid valves separating the atria and ventricles. The coordinated opening and closing of the heart valves occurs approximately three billion times in an average human lifespan and is required for unidirectional blood flow.9 The three cusps of each SL valve and the 2 (mitral) or 3 (tricuspid) leaflets of the atrioventricular (AV) valves consist of complex stratified connective tissue.9,10 The valve leaflets are ensheathed in endocardial endothelial cells with intervening valve interstitial cells (VICs) that function in homeostasis and disease.11,12 The valves are stratified into extracellular matrix (ECM) layers rich in elastin (ventricularis of SL/atrialis of AV), proteoglycan (spongiosa) and collagen (fibrosa), oriented relative to blood flow (Figure 1).12 The most obvious difference between the AV and SL valves is the presence of supporting chordae tendineae on the ventricular aspect of the tricuspid and mitral valves. However, comparable supporting connective tissue is present in the aortic and pulmonic roots and hinge regions of the SL valves.12,13 Morphogenetic and structural differences also exist among the individual mural and septal AV valve leaflets, but, in general, the molecular mechanisms of valve development are conserved among AV and SL valve leaflets. Extensive conservation of valve developmental mechanisms also has been observed among vertebrate species including chicken, mouse, and human.
The first evidence of valvulogenesis during embryonic development is the formation of endocardial cushions in the AV canal (AVC) and outflow tract (OFT) of the primitive looped heart tube.14,15 Valve primordia corresponding to individual leaflets and cusps are derived from the endocardial cushions, although the precise cushion origins of specific valve components are not well defined. For the AV valves, the septal valve leaflets are derived from the fused inferior and superior endocardial cushions that form in the AVC of the primitive heart tube, whereas the mural leaflets are derived from mesenchymal cushions that arise laterally in the AVC after cushion fusion.16 Less is known of how the SL valves arise from the complex arrangement of proximal and distal cushions that form in the OFT. The valve progenitor cells of the endocardial cushions are highly proliferative, whereas little or no cell cycling is apparent later in remodeling and mature valves.11,12,17 The valve primordia continue to grow and elongate into thin fibrous leaflets of the AV valves and cusps of the SL valves, with increased ECM deposition and remodeling.12 This process differs somewhat for individual valve leaflets. For example, the septal leaflet of the tricuspid valve delaminates from the closely apposed muscular ventricular septum, in contrast to the corresponding mitral valve leaflet that protrudes into the ventricular lumen much earlier in its development.16–19 During late gestation and soon after birth, the valve leaflets become stratified into highly organized collagen-, proteoglycan-, and elastin-rich ECM compartments.12,19 In mammals, valve maturation and remodeling continues into juvenile stages.11–13
Cell lineage studies in mice, based on examination of Tie2-Cre expressing cells and their derivatives, demonstrate that the majority of the cells present in the valves after birth are of endothelial endocardial cushion origin.16,17 These studies demonstrate that few, if any, cells of myocardial origin are present in the valve leaflets.16 Likewise, in avians, myocytes are absent from the mature heart valves, with the exception of the mural aspect of the tricuspid valve, which is almost entirely muscle.17,20 Although neural crest and secondary heart field cells are in close proximity to the SL valves, the leaflets themselves are predominantly of endothelial endocardial cushion origin.16,21 However, there are neural crest–derived melanocytes and dendritic cells of unknown function on the surface of the mature SL and AV valves.13,22–24 Epicardium-derived cells also have been identified as a source of valve progenitor cells, based on quail chick transplantation studies.25 Although cell lineage analysis of the chicken proepicardium does not show valve cell investment,26 Cre-positive cells are apparent in the developing valves of Tbx18-Cre and WT-1Cre mice.27,28 However, studies by de Lange et al demonstrate no investment of epicardial cells in the mature avian valves and conclude that all four valves in mice are almost entirely of endothelial origin.16 Overall, multiple lines of evidence support the conclusion that the mature valves are derived from endothelial endocardial cushion progenitors with little or no contribution from other cell types.
Comparison of adult aortic valve leaflet structure and composition demonstrates similar stratification in humans, sheep, chickens, rabbits, and mice.12 Although hearts with multiple chambers and valves evolved in response to the demands of separate systemic and pulmonary circulation required for terrestrial life, the molecular pathways and cellular processes of valve formation have their origins in simpler hearts that also drive unidirectional fluid flow. Conserved valve cell regulatory mechanisms consisting of signaling pathways and transcription factors have been reported in ostia cells of the Drosophila dorsal vessel.29,30 In zebrafish, endocardial cushions form in the primitive heart tube, although there is some debate regarding whether the cellular events of early endocardial cushion formation are conserved.31,32 Recently, high-speed imaging of zebrafish heart valve development demonstrated that the endocardial cushions form initially by invagination of the endocardium, and not an epithelial-to-mesenchymal transition (EMT) of endocardium at the AVC, as is observed in avians and mammals.32 However, the mature AV valve of the adult zebrafish 2-chambered heart is structurally similar to the mammalian AV valves with stratified ECM and supporting chordae tendineae.33 Therefore, the major cellular and molecular events of valve development are largely conserved among animals with hearts composed of multiple chambers.
Since the initial reports of endocardial cushion composition by Markwald and colleagues in the late 1970s,34,35 the study of heart valve development has expanded to include investigation of signaling and transcriptional mechanisms that control many aspects of valve development and function. These studies encompass a broad spectrum of approaches and animal model systems with relevance to human congenital and postnatal valve abnormalities. Here we focus on the molecular regulation of valve development in hearts with four chambers, based on human disease mutation analysis, genetic studies in mice, and embryological manipulations in avians.
Endocardial Cushion Formation and EMT
The first evidence of endocardial cushion formation is swellings that appear in the AVC and OFT regions of the looping heart (embryonic day [E]3 chick, E9.5 mouse, E31 to E35 human).36–38 Endocardial cushion formation is induced by myocardial production of signaling molecules that inhibit expression of chamber-specific genes in the AVC and OFT, while increasing synthesis of ECM components (Figure 2A).39–42 This increased ECM or “cardiac jelly” deposition between the myocardium and endocardium, along with the hydrophilic nature of the ECM proteoglycans, causes the tissue to protrude or swell into the interior lumen of the heart forming the endocardial cushions.35,43,44 Even at this early stage, endocardial cushions act as physical barriers that prevent the backflow of blood through the primitive heart tube.15 Signaling molecules originating from both the myocardium and endocardium of the AVC and OFT are necessary for proper endocardial cushion formation and EMT of endocardial endothelial cells (Figure 2B).45 EMT occurs as a subset of endocardial cushion endothelial cells break connections with neighboring cells and migrate into the cardiac jelly to populate the endocardial cushions with mesenchymal cells. The processes of endocardial cushion formation and EMT have been extensively studied using in vitro cell culture as well as in vivo model systems.
In general, the regulatory interactions and cellular events of valvulogenesis are conserved in AVC and OFT cushion development. The AVC cushions develop approximately 1 day earlier than the OFT cushions, and the examination of the OFT cushions is complicated by the presence of neural crest–derived progenitors that form the aorticopulmonary septum.46,47 Defects in secondary heart field development also preferentially compromise SL, but not AV, valve development related to defects in OFT morphogenesis48,49 (for a review, see Rochais et al50). Many of the molecular regulatory hierarchies that control early stages of valvulogenesis have been defined using AVC explants from mouse or chick embryos because of the larger size and accessibility of avian cushion tissue. In vivo studies confirm that these interactions also occur in the developing OFT cushions with the exceptions noted below.
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor (TGF)β superfamily and signal predominantly through activation of SMAD1/5/8.51 Data collected using both in vitro primary cell culture and in vivo model systems suggests that BMPs act as the major myocardially derived signals for initiation of endocardial cushion formation and EMT. BMP2 and 4 are expressed in the AVC and OFT myocardium during endocardial cushion morphogenesis in chick and mouse.52,53 Mice lacking myocardial BMP2 expression fail to express Tbx2 in AVC myocardium, which is necessary for suppression of chamber-specific gene expression and for increased ECM deposition in this region.42,54 Studies using mouse AVC explants demonstrated that BMP2 is sufficient to increase TGFβ2 expression and initiate EMT in AVC endothelial cells.55 The role for BMPs in initiation of EMT is further supported by in vivo analysis of mice lacking myocardial BMP2 expression, which show no AVC endocardial cushion mesenchymal cell formation.42,54 Mice lacking expression of BMP receptor-1a in the endocardium also exhibit decreased phospho-SMAD1/5/8 activity and defective EMT in the AVC, further substantiating the requirement for BMP receptor signaling in endocardial cushion endothelial cells during EMT. Aberrant BMP signaling results in downregulation of multiple EMT-related pathways in AVC endocardial cushions, including TGFβ and Notch1, as well as decreased expression of transcription factors such as Twist1 and Msx2.42 Taken together, these studies demonstrate a role for BMPs as important myocardially derived signals that initiate endocardial cushion formation and EMT.
TGFβs were among the first signaling molecules to be implicated in initiation of endocardial cushion EMT.56 TGFβ ligands and receptors are expressed in the AVC and OFT during endocardial cushion formation and EMT in avian and murine embryos. In both chick and mouse model systems, TGFβ ligands and receptors are required for EMT, however, species-specific differences have been noted.14 TGFβ signaling through SMADs 2/3 induces expression of the transcription factor Slug, which promotes AVC endocardial cushion endothelial cell activation and invasion during EMT.57,58 TGFβ activity has also been associated with increased β-catenin signaling during AVC endocardial cushion EMT in mice.59 Mice harboring genetic deletion of β-catenin in cells of the Tie-2 lineage fail to populate AVC endocardial cushions with mesenchymal cells because of defective EMT.59 In zebrafish, overexpression of Wnt inhibitors adenomatous polyposis coli (APC) or Dickkopf1 blocks AVC endocardial cushion formation, that likely occurs through invagination and not EMT.32,60 Together, these studies suggest that TGFβ and Wnt/β-catenin signaling are important inducers of endocardial cushion formation, but the regulatory relationships of these pathways have not been defined.
Notch signaling also plays an indispensable role in endocardial cushion EMT. The Notch signaling ligand Delta4 and receptors Notch1–4 are expressed by endocardial cushion endothelial cells of the AVC and OFT before and throughout EMT.61 In mice that lack expression of Notch1 or the interacting transcription factor recombination signal binding protein for immunoglobulin κJ region (RBPJK), the AVC and OFT endocardial cushion swellings are present, but are devoid of mesenchymal cells because of a failure of EMT. In Notch signaling mutants, endocardial cushion endothelial cells extend processes into the cardiac jelly, but they are unable to delaminate and migrate into the ECM. In addition, Notch signaling induces expression of the promigratory transcription factor Snail in AVC and OFT endocardial cushion endothelial cells undergoing EMT. Snail directly represses VE-cadherin promoter activity, thereby allowing activated mesenchymal cells to break contact with neighboring cells and migrate into the endocardial cushion interior. Notch signaling also is required for expression of TGFβ2 and multiple TGFβ receptors in AVC and OFT endocardial cushion endothelial cells, serving to further promote EMT. Mutations in Notch signaling components in humans are associated with a spectrum of cardiac abnormalities, including defects in tissues derived from AVC and OFT endocardial cushions.6,62 These observations suggest that Notch signaling is dispensable for initial ECM deposition during formation of endocardial cushion swellings but is required for endocardial cushion endothelial cell EMT.
During endocardial cushion formation, the AVC myocardium secretes biologically active adheron-like protein complexes containing ES1, fibronectin, transferrin, ES130, hLAMP1, and other extracellular components to activate adjacent endothelial cells and induce EMT.45,63–67 Proper function of these and other signaling components during AVC endocardial cushion formation and EMT requires the appropriate ECM environment. The endocardial cushion ECM is a hydrated matrix that provides physical support for mechanical function, promotes the invasive phenotype of mesenchymal cells, and serves as a scaffold for cell migration.15,43 Disruption of hyaluronan synthase-2 (has2) or versican gene expression in mice prevents AVC endocardial cushion formation, and hyaluronan also is required for mesenchymal cell migration associated with EMT.43,68 ErbB receptor activation is coupled to hyaluronan function in endocardial cushion EMT, because addition of heregulin to has2−/− AVC explants rescues EMT.47,69 Furthermore, ErbB3−/− null mice exhibit lethality at E13.5 with hypoplastic AVC endocardial cushions because of lack of adequate EMT. Because of its diverse functions, ECM synthesis must be properly regulated to ensure that the resulting extracellular environment has the appropriate physical and molecular characteristics to support endocardial cushion formation and EMT.
Growth of Endocardial Cushions and Valve Primordia
After EMT, the endocardial cushions and subsequent valve primordia undergo growth via cell proliferation and continued ECM synthesis.12,36,70 The AVC valve primordia are part of a larger mass of tissue called the septum intermedium that is formed via fusion of the endocardial cushions at E4.5 in chicks, E11.5 in mice, and E37 to E42 in humans.36,38,71,72 Septum intermedium tissue contributes to the membranous ventricular septum and fibrous continuity overlying the ventricular septum adjacent to the valve primordia that form the septal tricuspid and mitral valve leaflets.36 The OFT endocardial cushions also fuse and contribute to the formation of the aortic and pulmonary valve leaflets and supporting structures.73 Molecular mechanisms regulating growth of post-EMT endocardial cushions and valve primordia are reviewed below.
Endocardial cushion and valve primordia mesenchymal cell proliferation is both positively and negatively regulated during growth of these structures (Figure 3). BMPs promote growth, as BMP4 mouse mutants display hypocellular AVC and OFT valve primordia that remain unremodeled.74,75 Double mutants for BMP6/7 and those harboring BMPRII mutations have hypoplastic OFT valve primordia with grossly normal AVC, demonstrating an important difference in the local requirements for BMP6/7 signaling.76,77 Conversely, genetic deletion of the BMP inhibitory SMAD, SMAD6, in mice results in AVC and OFT valve primordia hyperplasia, further illustrating the need for proper levels of BMP signaling to achieve normal valvulogenesis.78 Fibroblast growth factors (FGFs) also promote post-EMT endocardial cushion/valve primordia mesenchymal cell proliferation. FGF4 is expressed throughout the AVC and OFT of chick embryos during growth of endocardial cushions and valve primordia, whereas expression of FGF receptors 1, 2, and 3 is restricted to endocardial cushion/valve primordia cells.79 FGF4 treatment of chick AVC endocardial cushion explants or injection of replication defective retrovirus containing FGF4 coding sequence into chick hearts in ovo increases mesenchymal cell proliferation and results in hyperplastic AVC valve primordia. Conversely, epidermal growth factor (EGF) signaling inhibits endocardial cushion and valve primordia mesenchymal cell proliferation through antagonism of BMP-mediated activation of SMAD1/5/8 in the AVC and OFT.14 Therefore, mutations causing reduced EGF signaling result in hypercellular AVC and OFT valve primordia.80,81 These data demonstrate complex regulation of mesenchymal cell proliferation during endocardial cushion/valve primordia growth.
In humans, mutations in several genes impinging on the Ras/mitogen-activated protein kinase pathway, including protein tyrosine phosphatase nonreceptor type 11 (PTPN11), which encodes the protein tyrosine phosphatase SHP2, cause Noonan syndrome.82 Noonan syndrome is associated with multiple congenital defects including cardiac abnormalities in tissues derived from AVC and OFT endocardial cushions.83 SHP2 promotes Ras/mitogen-activated protein kinase activation and also acts downstream of EGF and other growth factor receptors.83,84 Mice bearing activating SHP2 mutations in Tie-2 expressing cells have increased extracellular signal-regulated kinase (ERK)1/2 activation and increased proliferation of AVC and OFT endocardial cushion/valve primordia endothelial and mesenchymal cells.84 This phenotype is rescued by genetic deletion of ERK1. It is hoped that further studies of mouse models such as these will lead to better understanding of, and therapies for, Noonan syndrome.
Canonical Wnt signaling is active in growing AVC and OFT endocardial cushions and valve primordia.59,60,85 Wnt4 and Wnt9b are expressed by endothelial cells of the mouse AVC and OFT endocardial cushion and valve primordia, whereas Wnt2, Lef1, and the Wnt receptor Fzd2 are expressed in corresponding mesenchymal cells (CM Alfieri, J Cheek, S Chakraborty, KE Yutzey, unpublished data, 2009). Wnt9a is expressed in chick AVC endocardium, and introduction of replication competent retrovirus expressing Wnt9a leads to hypercellular valve primordia.86 The reverse phenotype is seen when avian AVC explants are treated with the Wnt inhibitor Frzb.86 Similarly, mutation of the Wnt signaling inhibitor APC in zebrafish causes increased AVC endocardial cushion and valve primordia mesenchymal cell proliferation.59,60,85 These data suggest that Wnt signaling must be tightly regulated during endocardial cushion/valve primordia growth to maintain proper levels of mesenchymal cell proliferation.
During growth of valve primordia and in cellularized endocardial cushions, mesenchymal cells are distributed throughout the ECM.12 This ECM is rich in hyaluronan, versican, and other basement membrane components, however, differentiating mesenchymal cells also begin to produce collagens 1, 2, 3, 4, and 9 as well as cartilage- and tendon-related ECM components such as aggrecan and tenascin.12,87–90 AVC endocardial cushion explant experiments as well as mouse models demonstrate a role for BMP-regulated transcription factors in maintaining a balance between endocardial cushion/valve primordia mesenchymal cell proliferation and differentiation. Tbx20 and Twist1 are expressed by AVC endocardial cushion/valve primordia cells during growth of these structures and are associated with high levels of valve cell proliferation as well as expression of promigratory genes such as periostin, cadherin-11, and matrix metalloproteinase 2 (MMP2).91,92 Sox9, another BMP-regulated transcription factor, also promotes cell proliferation and maintenance of proper ECM architecture during endocardial cushion/valve primordia growth.93,94 Sox9 mutant embryos have hypocellular AVC and OFT endocardial cushions because of defective proliferation of mesenchymal cells and display dysmorphic valve primordia ECM. Furthermore, expression of transcription factors Msx1/2 in OFT myocardium and endocardial cushion/valve primordia cells induces expression of BMP4, which negatively regulates OFT endocardial cushion and valve primordia mesenchymal cell proliferation.95 Therefore, Msx1/2 double mutants exhibit hypercellular SL valve primordia. It is clear that a complex network of transcription factors is necessary to promote proper levels of endocardial cushion/valve primordia mesenchymal cell proliferation and maintain the appropriate ECM architecture during endocardial cushion/valve primordia growth.
Endocardial cushion initiation, EMT, and growth of endocardial cushions and valve primordia are associated with high levels of endothelial cell proliferation.12,35,36 Vascular endothelial growth factor A (VEGF) is a potent cytokine that promotes endothelial cell proliferation as well as survival.96 VEGF is highly expressed by myocardium and endocardium before endocardial cushion formation, however, endocardial VEGF expression becomes restricted to endothelial cells of the AVC and OFT during endocardial cushion initiation, EMT, and growth of valve primordia.97,98 VEGF receptor (VEGFR)1 and -2 are expressed throughout the endocardium; however, VEGF and VEGFR expression is absent in mesenchymal endocardial cushion/valve primordia cells. Studies in chick, mouse, and zebrafish demonstrate that VEGF signaling contributes to AVC and OFT endocardial cushion cell proliferation.96,98,99 VEGF signaling also inhibits AVC endocardial cushion EMT by promoting maintenance of an endothelial cell phenotype, thereby maintaining a proliferative population of endothelial cells throughout endocardial cushion formation, EMT, and endocardial cushion/valve primordia growth. VEGF expression must be strictly controlled during endocardial cushion EMT and endocardial cushion/valve primordia growth, as overexpression inhibits EMT, whereas underexpression of VEGF results in failure to maintain a proliferative endothelial cell population.
NFATc1 (nuclear factor of activated T cells cytoplasmic 1) is an NFAT family transcription factor expressed by AV and SL endocardial cushion/valve primordia endothelial cells throughout growth and remodeling.100–102 NFATc1−/− mouse embryos have normal initiation of endocardial cushion formation and EMT. However, established AVC endocardial cushions have a reduced proliferative index, and AV and SL valve primordia fail to undergo remodeling, with embryonic lethality by E14.5.100,101,102a In cultured chicken AVC endocardial cushion cells, VEGF promotes endothelial cell proliferation through NFATc1 activation (Combs and Yutzey, unpublished data). Likewise, VEGF treatment of human pulmonary valve endothelial cells induces NFATc1-dependent proliferation demonstrating a role for this interaction in adult valve homeostasis.103 VEGF and NFATc1 expression are extinguished in AVC and OFT endocardial cushion mesenchymal cells upon EMT but are maintained in the overlying endothelial cell layer.97,100,101 Concomitant with valve remodeling, VEGF expression in AVC valve primordia endothelial cells is downregulated and valve endothelial cell proliferation is greatly diminished, whereas AV and SL valve endothelial cell NFATc1 expression is maintained.12,97,102
RANKL (receptor activator of nuclear factor κB ligand), an upstream activator of NFATc1, is expressed in AV and SL valve endothelial cells during the transition from valve primordia growth to remodeling.102,102a RANKL treatment of primary chicken AVC endocardial cushion cells activates NFATc1 to induce expression of ECM remodeling enzymes, such as Cathepsin K (CtsK), while inhibiting cell proliferation.102a Likewise, RANKL treatment of cultured mouse hearts increases NFATc1 and CtsK transcription.102 CtsK is normally expressed in AV and SL valve endothelial cells during remodeling, however, NFATc1−/− mice lack expression of this proteinase and their valves remain unremodeled.100–102 These data suggest NFATc1 serves as a nodal point in the transition from growth of valve primordia via endothelial cell proliferation to valve remodeling.
Diversification of Valve Cell Types
During fetal stages of the chicken (E14), mouse (E16.5 to 17.5), and human (20 to 39 weeks gestation), the valve primordia elongate into thin valve leaflets. Valve patterning is evident in differential gene expression on the surface of the valve exposed to unidirectional pulsatile blood flow versus the side of the valve away from flow (Figure 1). Elastin expression is localized to the flow side of the valves, whereas organized collagen fibrils are apparent in the fibrosa layer away from blood flow.12,19,104 Additional specialized ECM compartments are the proteoglycan-rich spongiosa layer as well as the tenascin-rich chordae tendineae and supporting structures.17,89 Together, these ECM compartments are required for normal valve structure and function, with dysregulation leading to disease (see below). The developmental and molecular mechanisms regulating valve stratification currently are not known. Hemodynamics is often evoked as a driving force in valve development, and there is evidence that blood flow is required for valve maturation in zebrafish.105,106 However, it has been particularly difficult to manipulate blood flow in the four-chambered heart to determine specific effects on the developing valves, distinct from compromised myocardial function or embryonic viability.
One of the first indicators of valve polarity in mouse and chicken embryos that distinguishes the flow side versus fibrosa side is localized Notch pathway activation and expression of downstream effectors Hey/Hrt/Hesr1–2 on the flow side (TJ Mead, KE Yutzey, unpublished data, 2009).6,107 Mice lacking Hesr2 exhibit AV valve thickening and regurgitation after birth, providing evidence for Notch pathway activation in valve leaflet maturation.108 The role of Notch signaling in establishing polarity of the valves has not been established, but this signaling pathway appears to have multiple roles in valve development and disease.6,61 An attractive hypothesis is that shear stress on the flow side of the valve promotes localized Notch signaling, thereby initiating valve polarity and stratification, but this has not yet been demonstrated.
There is emerging evidence for diversified cell types in the developing valves that give rise to distinct gene expression profiles associated with ECM compartments (Figure 4). However, the commitment of VICs to fixed lineages has not been unequivocally demonstrated. Likewise, the specific origin of VICs in distinct valve compartments has not been defined by fate mapping or cell lineage analysis of subpopulations or individual valve progenitors in vivo. The examination of the regulatory hierarchies controlling specialized cell types in the valves has been aided by studies of corresponding connective tissue types in other organ systems. Signaling pathways required for cell lineage development in cartilage, tendon and bone are active during valve remodeling.109 For example, transcription factors involved in cartilage and tendon development are localized to subsets of valve progenitor cells and are required for valve differentiation and patterning.89,94,110 In addition, the upstream regulators and downstream targets of these transcription factors also are expressed together in the developing valves. Overall, there is increasing evidence that development of distinct ECM compartments with specific biomechanical properties in the valves shares molecular regulatory mechanisms with other connective tissue types of similar ECM composition.
The spongiosa layer of the valve leaflets is rich in chondroitin sulfate proteoglycans that provide a compressible ECM similar to cartilage.9 In addition, the valve leaflets express the transcription factor Sox9 and structural proteins aggrecan, collagen2a1 and cartilage link protein, characteristic of cartilaginous structures.89,94,111 In contrast, valve supporting structures, including the chordae tendineae, are composed of elastic matrix similar to that observed in tendons, and both express the basic helix–loop–helix transcription factor scleraxis as well as tenascin and collagen 14.88,89,110 In cultured AVC or OFT valve progenitor cells, BMP2 treatment promotes expression of Sox9 and aggrecan, whereas FGF4 treatment promotes expression of scleraxis and tenascin.89,112 These 2 pathways antagonize each other in induction of lineage-specific gene expression in the developing valve progenitor cells, as was also observed in the developing limb buds.113,114 In vivo, Sox9 is required early in proliferation of the AVC and OFT endocardial cushion mesenchyme and later in expression of collagen2a1 and cartilage link protein in the differentiated AV valves.94 Likewise, loss of scleraxis results in decreased collagen 14 expression as well as increased expression of cartilage marker genes and abnormal valve ECM organization.110 Together, these studies provide evidence that multipotential valve progenitors of the endocardial cushions differentiate into cells of the valve spongiosa layer or supporting apparatus depending on exposure to BMP or FGF signaling, respectively.
Less is known of development of the valve fibrosa layer. During heart valve remodeling, ECM proteins characteristic of fibroblasts and preosteoblast lineages are restricted to the fibrosa layer, oriented away from blood flow (CM Alfieri, J Cheek, S Chakraborty, KE Yutzey, unpublished data, 2009).12,19 These ECM proteins include osteonectin, periostin, collagens 1 and 3, and fibronectin that contribute to the highly organized collagen matrix, conferring stiffness necessary for valvular sufficiency.115–117 The mature aortic valve fibrosa layer is the usual site of pathological calcification, and the coexpression of collagen1, osteonectin, and periostin is characteristic of fibrous connective tissues with the potential to mineralize, such as bone or dermal fibroblasts.118,119 Likewise, cultured aortic VICs express fibrosa markers and can be induced to express osteogenic markers under conditions that also promote mineralization of bone (CM Alfieri, J Cheek, S Chakraborty, KE Yutzey, unpublished data, 2009).120,121 Wnt signaling has been implicated in bone lineage development as well as aortic valve calcification.122–124 Multiple Wnt ligands, including Wnt3a and Wnt7b involved in bone development, are expressed together with the Wnt pathway reporter TOPGAL in remodeling mouse AV and SL valve leaflets (CM Alfieri, J Cheek, S Chakraborty, KE Yutzey, unpublished data, 2009).85 In addition, Wnt treatment of avian embryo aortic VICs in culture promotes expression of periostin (CM Alfieri, J Cheek, S Chakraborty, KE Yutzey, unpublished data, 2009). Together these analyses provide initial evidence for Wnt regulation of fibrosa layer maturation as well as conserved regulatory pathways with osteogenic cell lineages. Further studies are necessary to determine the requirements for Wnt signaling in heart valve stratification and disease mechanisms.
Heart Valve ECM Maturation and Organization
Heart valve development is characterized by increasing complexity and organization of the ECM. The ECM of endocardial cushions before EMT is rich in hyaluronan, and the mesenchymal cells in the cushions after EMT express network collagens and MMPs 1, 2, and 13, that promote cell migration.88,91,92,125 Electron microscopic studies show high cellularity and relatively unstructured ECM in endocardial cushions and valve primordia.12,35 Biomechanical studies of avian AVC endocardial cushions demonstrate increased rigidity of the tissue with increased cellularity and collagen deposition over time.126 Selective degradation of ECM components of endocardial cushions demonstrated that glycosaminoglycans in the cellularized cushions confer elasticity, whereas collagen provides rigidity.126 In the stratified valves, the structurally distinct layers of ECM provide specific biomechanical properties. Elastin fibers, of the ventricularis layer of SL and atrialis layer of the AV valves, confer elasticity to the valve, extending when the valve is open and recoiling when the valve is closed.9 The relatively unstructured proteoglycans of the spongiosa layer absorb compressible forces on the leaflets and mediate movements between the highly structured elastin fibrils of the ventricularis/atrialis and fibrous collagen of the fibrosa layer.9 The collagen-rich fibrosa layer provides stiffness and strength to the valve leaflet and is the major structural component of the valves. The collagen composition of the valves changes during maturation of the valve leaflets, with increased mature collagen fibrils at later stages, corresponding to increased structural and functional demands.88,90,104 Fibrous collagen is the most abundant protein in the mature valves, and the fibrosa layer is predominantly collagen 1 fibrils, but collagen 3 fibrils also are present.9,12,19 Overall, the precise regulation and organization of the complex layers of the valve ECM is critical for normal valve development, structure and function.
Abnormal expression and distribution of ECM proteins expressed in the valves is associated with developmental valve abnormalities and disease (Tables 1 and 2⇓). Elastin mutations are associated with Williams syndrome, which includes supravalvular aortic stenosis as well as SL valve disease.127 Loss of elastin in mice leads to arterial abnormalities and perinatal death before significant investment in the stratified valves.128 However, elastin heterozygous mutant mice exhibit aortic valve anomalies, thus demonstrating the importance of elastin in normal valve structure and function (RB Hinton, J Adelman-Brown, S Witt, VK Krishnamurthy, MJ Gruber, H Osinska, B Sakthivel, DA Narmoneva, RP Mecham, DW Benson, unpublished data, 2009). Marfan syndrome, which includes aortic valve anomalies in addition to aortic dilation, is caused by mutations in fibrillin-1, also present in aortic valve elastic fibrils.129 Likewise, mice lacking the associated elastic fibril ECM protein fibulin-4 exhibit thickening and calcification of the aortic valve.130 Proteoglycan gene mutants have not yet been associated with defects in the stratified valves, but increased synthesis and disorganization of proteoglycans is predominant in pediatric aortic valve disease and adult myxomatous mitral valves.12,131 It seems likely that additional ECM gene mutations contribute to isolated and familial congenital valve malformations, and ECM genes expressed in the valves are certainly strong candidates in ongoing human genetic analyses.
Complex regulation of collagen composition is an important feature of valve maturation and homeostasis. Mutations in multiple collagen genes are associated with connective tissue disorders that include valve dysfunction and disease. Osteogenesis imperfecta is caused by collagen 1a1 mutations that can lead to mitral and/or aortic valve insufficiency necessitating replacement, in addition to prevalent skeletal and vascular anomalies.132,133 Ehlers–Danlos syndrome is associated with mutations in collagens 3, 5, 11, or tenascin X, and Stickler syndrome is caused by collagen 2 or 11 mutations.134–136 Both of these syndromes include widespread connective tissue disease, as well as heart valve dysfunction, that can be severe enough to necessitate replacement.137,138 Dysregulation of the expression and distribution of fibrous collagen in the valves occurs in valve disease, with increased collagen 3 relative to collagen 1 fibrils in myxomatous mitral valves.139 In mice, targeted mutagenesis of facit collagen genes collagen 5a1 and 11a1 results in thickening of SL and AV valves with increased expression of fibrous collagens 1 and 3 evident at birth.140 Similarly, loss of periostin, which regulates collagen fibrillogenesis, also leads to congenital AV and SL valve anomalies that compromise heart valve structure and function.116,117 Overall, a variety of lesions related to collagen dysregulation are linked to defects in valve development and also in valve disease.
Heart Valve Development and Disease
There is increasing evidence for a link between congenital valve malformations and late-onset valve disease. The most common valve malformation is bicuspid aortic valve (BAV), which often goes undetected until the valve becomes stenotic and requires replacement late in life.141 Prenatally, there is increasing evidence that aortic valve malformations can lead to more severe congenital heart anomalies, including hypoplastic left heart.142,143 BAV is heritable, and mutations in the NOTCH1 gene have been associated both with BAV and aortic valve calcification.6,141 Aortic valve calcification has been characterized as an osteogenic process with activation of several genes involved in bone mineralization, including Runx2 and osteocalcin.144–146 In developing bone progenitors, Notch1 signaling inhibits mineralization by repressing the transcriptional activity of Runx2, and a related mechanism has been evoked as a protective mechanism in aortic valve disease.6,147 Increased Wnt signaling, also implicated in valve and bone development and antagonized by Notch signaling, is associated with aortic valve disease.122,147 Therefore, signaling pathways involved in normal valve development likely have both positive and negative effects in valve pathogenesis that could be exploited in the treatment of these common conditions.
In the normal adult valve, the VICs are relatively quiescent with little or no synthetic activity or cell proliferation.12,104 The most common types of valve disease are myxomatous, characterized by insufficiency and inappropriate ECM production, and stenotic, with leaflets that are thickened, stiff, and mineralized.10,118 Activation of VICs with increased synthetic activity is observed with both types of valve pathogenesis.11,12,146 It is not known whether VICs can reenter the cell cycle under pathological conditions. Recent studies have begun to define distinct types of VICs that may have specific roles in valve pathogenesis, and these may be related to diversified cell types seen during development.121 In addition, bone marrow–derived hematopoietic stem cells have been reported to be present in adult valves, but the function of these cells in valve homeostasis and pathogenesis has not been defined.148 There is initial evidence that the increased ECM production and VIC activation in valve pathogenesis is related to developmental pathways, but further studies are necessary to rigorously test this hypothesis.6,122,146,149
Conclusions and Perspectives
Complex regulatory mechanisms that govern normal and abnormal valve development have been defined as a result of the work of many laboratories using a variety of experimental systems. This work has identified conserved regulatory hierarchies involving signaling pathways and transcriptional mechanisms active during both early and late valve development, as well as in other related types of connective tissue. Still, there are many remaining questions to be addressed in the study of valve development. Although the majority of cells in the mature valve are of endothelial cushion origin, specific contributions of epicardial- and neural crest–derived cells have yet to be fully defined. In addition, further studies are necessary to map the specific fates of individual endocardial cushion cells in the stratified valves and to determine the plasticity of mature VICs. Likewise, little is known of how the common endocardial cushions contribute to specific valve leaflets, especially for the SL valves. In general, individual reports on valvulogenesis have focused on regulatory interactions acting in isolation at specific times and in specific cells of the developing valves. Further studies are necessary to fully define the interactions of these many regulatory pathways to have a more complete understanding of how valves form during prenatal development and how alterations in these processes lead to valve dysfunction and disease.
The emerging evidence for activation of valve developmental pathways during adult valve disease pathogenesis has potentially important implications in the treatment of human cardiovascular disease.10,11,131,144 It is not known whether VICs that express valve developmental genes represent a dedifferentiated cell type or whether there is a relatively undifferentiated cell population in normal adult valves. Alternatively, cells from extracardiac origins, such as mesenchymal or hematopoietic stem cells, may populate the adult valves and could contribute to disease pathology or have valve regenerative potential.148 A valve stem cell population has not been identified. The detailed analysis of regulatory pathways that control valve development also has implications in valve tissue engineering. In general, efforts directed toward generating engineered valves do not take into account the diversity of VICs or their abilities to generate ECM with distinct structural characteristics.150 The application of recent research into valve developmental mechanisms to the generation of engineered valves will likely improve the long-term function of these tissue constructs and could lead to improved therapeutics or replacement strategies. Likewise, manipulation of known valve developmental mechanisms could be applied to the treatment and management of the most common types of valve disease.
We thank Robert Hinton, Jr, as well as Christina Alfieri, Timothy Mead, Santanu Chakraborty, and Jonathan Cheek in the laboratory of K.E.Y. for communication of results before publication.
Sources of Funding
Work in the laboratory of K.E.Y. is supported by grants from NIH/National Heart, Lung, and Blood Institute, including R01HL82716, and M.D.C. is supported by a Predoctoral Fellowship from the American Heart Association-Great Rivers Affiliate.
Original received May 23, 2009; revision received July 2, 2009; accepted July 23, 2009.
Pierpont ME, Basson CT, Benson DW Jr, Gelb BD, Giglia TM, Goldmuntz E, McGee G, Sable CA, Srivastava D, Webb CL. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young. Circulation. 2007; 115: 3015–3038.
Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005; 111: 920–925.
Kirk EP, Sunde M, Costa MW, Rankin SA, Wolstein O, Castro ML, Butler TL, Hyun C, Guo G, Otway R, Macay JP, Waddell LB, Cole AD, Hayward C, Keogh A, Macdonald P, Griffiths L, Fatkin D, Sholler GF, Zorn AM, Feneley MP, Winlaw DS, Harvey RP. Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am J Hum Genet. 2007; 81: 280–291.
Schoen FJ. Evolving concepts of cardiac valve dynamics. Circulation. 2008; 118: 1864–1880.
Hinton RB, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, Yutzey KE. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res. 2006; 98: 1431–1438.
Hinton RB, Alfieri CM, Witt SA, Glascock BJ, Khoury PR, Benson DW, Yutzey KE. Mouse heart valve structure and function: echocardiographic and morphometric analyses from the fetus through the aged adult. Am J Physiol Heart Circ Physiol. 2008; 294: H2480–H2488.
de Lange FJ, Moorman AFM, Anderson RH, Manner J, Soufan AT, deGier-deVries C, Schneider MD, Webb S, Van Den Hoff MJ, Christoffels VM. Lineage and morphogenetic analysis of the cardiac valves. Circ Res. 2004; 95: 645–654.
Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. Fate of the mammalian cardiac neural crest. Development. 2000; 127: 1607–1616.
Nakamura T, Colbert MC, Robbins J. Neural crest cells retain multipotential characteristics in the developing valves and label the cardiac conduction system. Circ Res. 2006; 98: 1547–1554.
Choi J-H, Do Y, Cheong C, Koh H, Boscardin SB, Oh YS, Bozzacco L, Trumpfheller C, Park CG, Steinman RM. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med. 2009; 206: 497–505.
Gittenberger-de Groot AC, Vranken Peeters MP, Mentink MM, Gourdie RG, Poelmann RE. Epicardium-derived cells contribute a novel population to the myocardial wall and the atrioventricular cushions. Circ Res. 1998; 82: 1043–1052.
Reim I, Frasch M. The Dorsocross T-box genes are key components of the regulatory network controlling early cardiogenesis in Drosophila. Development. 2005; 132: 4911–4925.
Beis D, Bartman T, Jin SW, Scott IC, D'Amico LA, Ober EA, Verkade H, Frantsve J, Field HA, Wehman A, Baier H, Tallafuss A, Bally-Cuif L, Chen JN, Stainier DYR, Jungblut B. Genetic and cellular analyses of zebrafish atrioventricular cushion and valve development. Development. 2005; 132: 4193–4204.
Scherz PJ, Juisken J, Sahai-Hernandez P, Stainier DY. High-speed imaging of developing heart valves reveals interplay of morphogenesis and function. Development. 2008; 135: 1179–1187.
Fishman MC, Chien KR. Fashioning the vertebrate heart: earliest embryonic decisions. Development. 1997; 124: 2099–2117.
Moorman A, Webb S, Brown NA, Lamers W, Anderson RH. Development of the heart: (1) formation of the cardiac chambers and arterial trunks. Heart. 2003; 89: 806–814.
Lyons KM, Pelton RW, Hogan BL. Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-2A (BMP-2A). Development. 1990; 109: 833–844.
Plageman TJ, Yutzey KE. Differential expression and function of Tbx5 and Tbx20 in cardiac development. J Biol Chem. 2004; 279: 19026–19034.
Harrelson Z, Kelly RG, Goldin SN, Gibson-Brown JJ, Bollag RJ, Silver LM, Papaioannou VE. Tbx2 is essential for patterning the atrioventricular canal and for morphogenesis of the outflow tract during heart development. Development. 2004; 131: 5041–5052.
Ma L, Lu MF, Schwartz RJ, Martin JF. Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. Development. 2005; 132: 5601–5611.
Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, Calabro AJ, Kubalak S, Klewer SE, McDonald JA. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest. 2000; 106: 349–360.
Henderson DJ, Copp AJ. Versican expression is associated with chamber specification, septation, and valvulogenesis in the developing mouse heart. Circ Res. 1998; 83: 523–532.
Park EJ, Watanabe Y, Smyth G, Miyagawa-Tomita S, Meyers E, Klingensmith J, Camenisch T, Buckingham M, Moon AM. An FGF autocrine loop initiated in second heart field mesoderm regulates morphogenesis at the arterial pole of the heart. Development. 2008; 135: 3599–3610.
Zhang J, Lin Y, Zhang Y, Lan Y, Lin C, Moon AM, Schwartz RJ, Martin JF, Wang F. Frs2alpha-deficiency in cardiac progenitors disrupts a subset of FGF signals required for outflow tract morphogenesis. Development. 2008; 135: 3611–3622.
Rochais F, Mesbah K, Kelly RG. Signaling pathways controlling second heart field development. Circ Res. 2009; 104: 933–942.
van Wijk B, Moorman AF, van den Hoff MJ. Role of bone morphogenetic proteins in cardiac differentiation. Cardiovasc Res. 2007; 74: 244–255.
Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, Dejana E. Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol. 2004; 166: 359–367.
Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC, delaPompa JL. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004; 18: 99–115.
Niessen K, Karsan A. Notch signaling in cardiac development. Circ Res. 2008; 102: 1169–1181.
Krug EL, Rezaee M, Isokawa K, Turner DK, Litke LL, Wunsch AM, Bain JL, Riley DA, Capehart AA, Markwald RR. Transformation of cardiac endothelium into cushion mesenchyme is dependent on ES/130: temporal, spatial, and functional studies in the early chick embryo. Cell Mol Biol Res. 1995; 41: 263–277.
Rezaee M, Isokawa K, Halligan N, Markwald RR, Krug EL. Identification of an extracellular 130-kDa protein involved in early cardiac morphogenesis. J Biol Chem. 1993; 268: 14404–14411.
Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004; 95: 459–470.
Webb S, Brown NA, Anderson RH. Formation of the atrioventricular septal structures in the normal mouse. Circ Res. 1998; 82: 645–656.
Wessels A, Sedmera D. Developmental anatomy of the heart: a tale of mice and man. Physiol Genomics. 2003; 15: 165–176.
Jiao K, Kulessa H, Tompkins K, Zhou Y, Batts L, Baldwin HS, Hogan BL. An essential role of Bmp4 in the atrioventricular septation of the mouse heart. Genes Dev. 2003; 17: 2362–2367.
Delot EC, Bahamonde ME, Zhao M, Lyons KM. BMP signaling is required for septation of the outflow tract of the mammalian heart. Development. 2003; 130: 209–220.
Krenz M, Yutzey KE, Robbins J. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Circ Res. 2005; 97: 813–820.
Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A. 2009; 106: 4736–4741.
Krenz M, Gulick J, Osinska H, Colbert MC, Molkentin JD, Robbins J. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome. Proc Natl Acad Sci U S A. 2008; 105: 18930–18935.
Chakraborty S, Cheek J, Sakthivel B, Aronow BJ, Yutzey KE. Shared gene expression profiles in developing heart valves and osteoblasts. Physiol Genomics. 2008; 35: 75–85.
Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, Epstein JA, de Crombrugghe B. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A. 2004; 101: 6502–6507.
Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development. 2000; 127: 3941–3946.
Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, Keshet E. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development. 2001; 128: 1531–1538.
Combs MD, Yutzey KE. VEGF and RANKL regulation of NFATc1 in heart valve development. Circ Res. In press.
Johnson EN, Lee YM, Sander TL, Rabkin E, Schoen FJ, Kaushal S, Bischoff J. NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells. J Biol Chem. 2003; 278: 1686–1692.
Aikawa E, Whittaker P, Farber M, Mendelson K, Padera RF, Aikawa M, Schoen FJ. Human semilunar cardiac valve remodeling by activated cells from fetus to adult. Circulation. 2006; 113: 1344–1352.
Butcher JT, Markwald RR. Valvulogenesis: the moving target. Phil Trans R Soc B. 2007; 362: 1489–1503.
Kokubo H, Miyagawa-Tomita S, Tomimatsu H, Nakashima Y, Nakazawa M, Saga Y, Johnson RL. Targeted disruption of hesr2 results in atrioventricular valve anomalies that lead to heart disfunction. Circ Res. 2004; 95: 540–547.
Levay AK, Peacock JD, Lu Y, Koch M, Hinton RB, Kadler KE, Lincoln J. Scleraxis is required for cell lineage differentiation and extracellular matrix remodeling during murine heart valve formation in vivo. Circ Res. 2008; 103: 948–956.
Wirrig EE, Snarr BS, Chintalapudi MR, O'Neal JL, Phelps AL, Barth JL, Fresco VM, Kern CB, Mjaatvedt CH, Toole BP, Hoffman S, Trusk TC, Argraves WS, Wessels A. Cartilage link protein 1 (Crtl1), an extracellular matrix component playing an important role in heart development. Dev Biol. 2007; 310: 291–303.
Snider P, Hinton RB, Moreno-Rodriguez R, Wang J, Rogers R, Lindsley A, Li F, Ingram DA, Menick D, Field L, Firulli AB, Molkentin JD, Markwald RR, Conway SJ. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res. 2008; 102: 752–760.
Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression and treatment strategies. Circulation. 2005; 111: 3316–3326.
Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of the two gla-containing proteins. J Cell Biol. 2004; 165: 625–630.
Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of hedgehog and wnt signaling in osteoblast development. Development. 2005; 132: 49–60.
Zhou H, Mak W, Zheng Y, Dunstan CR, Seibel MJ. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem. 2008; 283: 1936–1945.
Butcher JT, McQuinn TC, Sedmera D, Turner D, Markwald RR. Transitions in early embryonic atrioventricular valvular functions correspond with changes in cushion biomechanics that are predictable with tissue composition. Circ Res. 2007; 100: 1503–1511.
Hanada K, Vermeij M, Garinis GA, de Waard MC, Kunen MGS, Myers L, Maas A, Duncker DJ, Meijers C, Dietz HC, Kanaar R, Essers J. Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res. 2007; 100: 738–746.
Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001; 104: 2525–2532.
Prockop DJ, Colige A, Helminen H, Khillan JS, Pereira R, Vandenberg P. Mutations in type 1 procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies. J Bone Min Res. 1993; 8: S489–S492.
Ahmad NN, Ala-Kokko L, Knowlton RG, Jimenez SA, Weaver EJ, Maguire JI, Tasman W, Prockop DJ. Stop codon in the procollagen II gene (COL2A1) in a family with Stickler syndrome. Proc Natl Acad Sci U S A. 1991; 88: 6624–6627.
Ahmad NN, Richardson JA, Murfett HC, Shapiro L, Scott JD, Yates JR, Norton J, Snead MP. Prevalence of mitral valve prolapse in Stickler syndrome. Am J Med Genet. 2003; 116: 234–237.
Cole WG, Chan D, Hickey AJ, Wilcken DE. Collagen composition of normal and myxomatous human mitral heart valves. Biochem J. 1984; 219: 451–460.
Loffredo CA. Epidemiology of cardiovascular malformations: prevalence and risk factors. Am J Hum Genet. 2000; 97: 319–325.
Rajamannan NM, Subramaniam M, Rickard DJ, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg TC. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003; 107: 2181–2184.
Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006; 47: 1707–1712.
Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007; 115: 377–386.
Deregowski V, Gazzerro E, Priest L, Rydziel S, Canalis E. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling. J Biol Chem. 2006; 218: 6203–6210.
Visconti RP, Ebihara Y, LaRue AC, Fleming PA, McQuinn TC, Masuya M, Minamiguchi H, Markwald RR, Ogawa M, Drake CJ. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ Res. 2006; 98: 690–696.
Paruchuri S, Yang JH, Aikawa E, Melero-Martin JM, Khan ZA, Loukogeorgakis S, Schoen FJ, Bischoff J. Human pulmonary valve progenitor cells exhibit endothelial/mesenchymal plasticity in response to vascular endothelial growth factor-A and transforming growth factor beta2. Circ Res. 2006; 99: 861–869.
Walsh EC, Stainier DY. UDP-glucose dehydrogenase required for cardiac valve formation in zebrafish. Science. 2001; 293: 1670–1673.
George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 1993; 119: 1079–1091.
Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol. 1999; 147: 1109–1122.
Liu X, Wu H, Byrne M, Krane S, Jaenisch R. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci U S A. 1997; 94: 1852–1856.